UAE-FED-NATIONAL-COUNCIL
9.1.2019 19:16:14 CET | Business Wire | Press release
His Excellency Antonio Tajani, President of the European Parliament, expressed his deep appreciation for the UAE’s global humanitarian and relief efforts, manifested through the work of the Emirates Red Crescent and described them as “really impressive”.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190109005738/en/
His statement came during a brief speech delivered on Tuesday, January 8, 2019, during the opening of the three-day ‘Humanitarian Aid for Stability’ exhibition at the European Parliament in Brussels, Belgium. The event was organized by the Emirates Red Crescent in coordination with the Federal National Council (FNC), the parliamentary body of the UAE.
The opening of the exhibition drew the participation of Her Excellency Dr Amal Al Qubaisi, Speaker of FNC, His Excellency Fahad Abdelrahman Bin Sultan, Deputy Secretary General for International Aid at the Emirates Red Crescent, members of the European Parliament, and several ambassadors.
His Excellency Antonio Tajani called for joint action between the UAE and Europe to deal with illegal immigration, expand cooperation in this regard to the Middle East and Africa, and strengthen collaborative efforts to combat terrorism and enhance security. He added that ensuring stability and promoting development efforts in the world are common goals for the UAE and the EU.
His Excellency Antonio Tajani stressed that the refugee crisis is a global challenge, and therefore humanitarian aid must be a collective task that engages nations and peoples.
Furthermore, he thanked Antonio López-Istúriz White, Secretary General of the European People’s Party and member of the European Parliament, for his initiative in holding the exhibition that presented a novel opportunity to showcase the endeavors of valued partners of the EU to help alleviate the devastating effects of war. He added that war and natural disasters are the reasons for thousands of migrants trying to seek refuge in Europe.
His Excellency Antonio Tajani said: “The exhibition carries the positive message of hope. Yes, hope, because helping each other, providing a roof for people in need is providing hope, and hope is the fuel for a better tomorrow.”
In closing, he invited guests to view the exhibition that included a model of the Mrajeeb Al Fhood camp for Syrian refugees in Jordan and an interactive world map of areas in which the Emirates Red Crescent operates. He also highlighted the EU’s humanitarian commitment to helping refugees that places it at the forefront of humanitarian aid providers globally, and called for reinstating stability and security in the refugees’ home countries to overcome this global challenge.
Speaking on the sidelines of the launch of the exhibition, His Excellency Fahad Abdelrahman Bin Sultan said: “The humanitarian and development aid offered by the UAE to the world amounted to US$32.01 billion from 2013 to 2017 and benefited millions of people across the globe, including 10 million Yemenis.”
He added: “This exhibition is the first of its kind outside the UAE and was organized at the request of the European Parliament to explore the UAE’s international humanitarian, relief, and development role that is based on the country’s noble values and enhances the global humanitarian ecosystem.”
His Excellency Fahad Abdelrahman Bin Sultan stressed that the UAE humanitarian and development aid focuses on meeting the needs of refugees and displaced civilians in volatile areas, such as Syria, Yemen, Somalia, Palestine, Afghanistan, and Iraq. He pointed out that the UAE has gained international respect and trust, and placed first globally for the fifth consecutive year for its contribution of humanitarian and development aid relative to national GDP.
He noted that more than 100 countries have benefited from aid provided by the UAE, adding that the Emirates Red Crescent has 14 offices in countries such as Yemen, Somalia, Kazakhstan, Indonesia, Pakistan, Afghanistan, Bosnia, and Albania.
His Excellency Fahad Abdelrahman Bin Sultan outlined the distribution of the UAE humanitarian aid as follows: US$4.92 billion to Yemen from April 2015 to December 2018, around US$174.6 million to Libya from 2013 to 2017, around US$963.5 million to the Syrian people from 2012 to November 2018, around US$641.5 million to the people of Erbil (Iraq) from 2013 to 2017, around US$233.3 million to Somalia from 2013 to 2017, US$489 million to Palestinians from 2013 to 2018, and US$333.3 million to Afghanistan from 2013 to 2017.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20190109005738/en/
Contact:
Federal National Council, United Arab Emirates : Mohammed Al-Sawafi, +971506183874 m.alsawwafi@almajles.gov.ae Twitter: @FNC_UAE
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alnylam Presents New Data at ESC Congress 2026 Reinforcing Strength in RNAi-Powered TTR Silencing Across ATTR-CM Patient Populations and Treatment Settings30.8.2026 14:23:00 CEST | Press release
–Late-Breaking Prespecified Subgroup Analysis of HELIOS-B Demonstrates that Vutrisiran Provided Consistent Clinical Benefit Across All-Cause Mortality and Recurrent Cardiovascular Events in Patients With or Without Tafamidis Use at Baseline ––Additional Post Hoc Analyses Highlight Positive Impact of Vutrisiran in Addressing the Multisystemic Manifestations of ATTR-CM ––Pooled Analysis Across Four Positive Phase 3 Studies of Vutrisiran and Patisiran Shows Consistent Treatment Effect Across Sexes ––New Subgroup Analysis from KARDIA-3 Phase 2 Study of Zilebesiran Highlights Potential to Provide Enhanced Blood Pressure Control – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced new data at the European Society of Cardiology (ESC) Congress 2026 demonstrating the strength of RNAi-powered silencing for cardiovascular disease. The findings further reinforce the clinical profile of AMVUTTRA® (vutrisiran) across transthyretin amyloidosis (ATTR)
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom